Optimer axes chairman, CFO and VP over misconduct related to stock options
This article was originally published in Scrip
Executive Summary
Optimer Pharmaceuticals has removed chairman Dr Michael Chang from the company's board of directors for "his failure to identify and effectively manage compliance, record keeping and conflict of interest issues" in connection with stock options from the company's Taiwanese subsidiary, and fired chief financial officer John Prunty and vice-president Dr Youe-Kong Shue for their inaction regarding Dr Chang's alleged misconduct.